Suppr超能文献

慢性丙型肝炎病毒感染中特定阶段纤维化进展率的估计:一项荟萃分析和荟萃回归

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.

作者信息

Thein Hla-Hla, Yi Qilong, Dore Gregory J, Krahn Murray D

机构信息

University Health Network, Division of Clinical Decision-Making and Health Care Research, Toronto, Ontario, Canada.

出版信息

Hepatology. 2008 Aug;48(2):418-31. doi: 10.1002/hep.22375.

Abstract

UNLABELLED

Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage-specific fibrosis progression rates and their determinants in these individuals. A systematic review of published prognostic studies was undertaken. Study inclusion criteria were as follows: (1) presence of HCV infection determined by serological assays; (2) available information about age at assessment of liver disease or HCV acquisition; (3) duration of HCV infection; and (4) histological and/or clinical diagnosis of cirrhosis. Annual stage-specific transition probabilities (F0-->F1, ... , F3-->F4) were derived using the Markov maximum likelihood estimation method and a meta-analysis was performed. The impact of potential covariates was evaluated using meta-regression. A total of 111 studies of individuals with chronic HCV infection (n = 33,121) were included. Based on the random effects model, the estimated annual mean (95% confidence interval) stage-specific transition probabilities were: F0-->F1 0.117 (0.104-0.130); F1-->F2 0.085 (0.075-0.096); F2-->F3 0.120 (0.109-0.133); and F3-->F4 0.116 (0.104-0.129). The estimated prevalence of cirrhosis at 20 years after the infection was 16% (14%-19%) for all studies, 18% (15%-21%) for cross-sectional/retrospective studies, 7% (4%-14%) for retrospective-prospective studies, 18% (16%-21%) for studies conducted in clinical settings, and 7% (4%-12%) for studies conducted in nonclinical settings. Duration of infection was the most consistent factor significantly associated with progression of fibrosis.

CONCLUSION

Our large systematic review provides increased precision in estimating fibrosis progression in chronic HCV infection and supports nonlinear disease progression. Estimates of progression to cirrhosis from studies conducted in clinical settings were lower than previous estimates.

摘要

未标注

已发表的关于慢性丙型肝炎病毒(HCV)感染者肝纤维化进展的估计存在异质性。我们旨在评估这些个体中特定阶段的纤维化进展率及其决定因素。对已发表的预后研究进行了系统评价。研究纳入标准如下:(1)通过血清学检测确定存在HCV感染;(2)有关于肝病评估或HCV感染时年龄的可用信息;(3)HCV感染持续时间;(4)肝硬化的组织学和/或临床诊断。使用马尔可夫最大似然估计法得出年度特定阶段的转移概率(F0→F1,……,F3→F4),并进行了荟萃分析。使用荟萃回归评估潜在协变量的影响。共纳入了111项关于慢性HCV感染者(n = 33,121)的研究。基于随机效应模型,估计的年度平均(95%置信区间)特定阶段转移概率为:F0→F1 0.117(0.104 - 0.130);F1→F2 0.085(0.075 - 0.096);F2→F3 0.120(0.109 - 0.133);F3→F4 0.116(0.104 - 0.129)。所有研究中感染后20年肝硬化的估计患病率为16%(14% - 19%),横断面/回顾性研究为18%(15% - 21%),回顾性 - 前瞻性研究为7%(4% - 14%),临床环境中进行的研究为18%(16% - 21%),非临床环境中进行的研究为7%(4% - 12%)。感染持续时间是与纤维化进展显著相关的最一致因素。

结论

我们的大型系统评价提高了慢性HCV感染中纤维化进展估计的精度,并支持非线性疾病进展。临床环境中进行的研究对肝硬化进展的估计低于先前的估计。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验